Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 145 articles:
HTML format
Text format



Single Articles


    January 2017
  1. FAN CY, Huang WY, Lin KT, Lin CS, et al
    Lower Urinary Tract Infection and Subsequent Risk of Prostate Cancer: A Nationwide Population-Based Cohort Study.
    PLoS One. 2017;12:e0168254.
    PubMed     Text format     Abstract available


  2. PARK JY, Yoon S, Park MS, Choi H, et al
    Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
    PLoS One. 2017;12:e0168917.
    PubMed     Text format     Abstract available


  3. KAKEGAWA T, Bae Y, Ito T, Uchida K, et al
    Frequency of Propionibacterium acnes Infection in Prostate Glands with Negative Biopsy Results Is an Independent Risk Factor for Prostate Cancer in Patients with Increased Serum PSA Titers.
    PLoS One. 2017;12:e0169984.
    PubMed     Text format     Abstract available


  4. CHEN YA, Lien HM, Kao MC, Lo UG, et al
    Sensitization of Radioresistant Prostate Cancer Cells by Resveratrol Isolated from Arachis hypogaea Stems.
    PLoS One. 2017;12:e0169204.
    PubMed     Text format     Abstract available


  5. YU S, Wang Y, Yuan H, Zhao H, et al
    Knockdown of Mediator Complex Subunit 19 Suppresses the Growth and Invasion of Prostate Cancer Cells.
    PLoS One. 2017;12:e0171134.
    PubMed     Text format     Abstract available


  6. PITCHER B, Khoja L, Hamilton RJ, Abdallah K, et al
    Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS).
    PLoS One. 2017;12:e0170544.
    PubMed     Text format     Abstract available


  7. KENMOGNE LC, Roy J, Maltais R, Rouleau M, et al
    Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17beta-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.
    PLoS One. 2017;12:e0171871.
    PubMed     Text format     Abstract available


  8. YU XQ, Luo Q, Smith DP, Clements MS, et al
    Phase of care prevalence for prostate cancer in New South Wales, Australia: A population-based modelling study.
    PLoS One. 2017;12:e0171013.
    PubMed     Text format     Abstract available


  9. LEE CH, Huang G, Chan PH, Hai J, et al
    Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
    PLoS One. 2017;12:e0171495.
    PubMed     Text format     Abstract available


  10. FENG Z, Min X, Margolis DJ, Duan C, et al
    Evaluation of different mathematical models and different b-value ranges of diffusion-weighted imaging in peripheral zone prostate cancer detection using b-value up to 4500 s/mm2.
    PLoS One. 2017;12:e0172127.
    PubMed     Text format     Abstract available


  11. CHUNG SD, Kao LT, Lin HC, Xirasagar S, et al
    Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder.
    PLoS One. 2017;12:e0173266.
    PubMed     Text format     Abstract available


  12. LI CC, Hou YC, Yeh CL, Yeh SL, et al
    Retraction: Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Prostate Cancer Cell Migration and Invasion Induced by Tumor-Associated Macrophages.
    PLoS One. 2017;12:e0173325.
    PubMed     Text format    


  13. BLUTE ML JR, Damaschke N, Wagner J, Yang B, et al
    Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy.
    PLoS One. 2017;12:e0172048.
    PubMed     Text format     Abstract available


  14. MYUNG JK, Wang G, Chiu HH, Wang J, et al
    Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer.
    PLoS One. 2017;12:e0174134.
    PubMed     Text format     Abstract available


  15. SEO Y, Ryu K, Park J, Jeon DK, et al
    Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells.
    PLoS One. 2017;12:e0174935.
    PubMed     Text format     Abstract available


  16. LE B, Powers GL, Tam YT, Schumacher N, et al
    Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
    PLoS One. 2017;12:e0174658.
    PubMed     Text format     Abstract available


  17. LYNCH SM, Mitra N, Ross M, Newcomb C, et al
    A Neighborhood-Wide Association Study (NWAS): Example of prostate cancer aggressiveness.
    PLoS One. 2017;12:e0174548.
    PubMed     Text format     Abstract available


  18. FAN CY, Huang WY, Lin CS, Su YF, et al
    Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study.
    PLoS One. 2017;12:e0175217.
    PubMed     Text format     Abstract available



  19. Correction: Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
    PLoS One. 2017;12:e0175606.
    PubMed     Text format     Abstract available


  20. PANG KH, Rosario DJ, Morgan SL, Catto JW, et al
    Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.
    PLoS One. 2017;12:e0175070.
    PubMed     Text format     Abstract available


  21. ROHENA-RIVERA K, Sanchez-Vazquez MM, Aponte-Colon DA, Forestier-Roman IS, et al
    IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer.
    PLoS One. 2017;12:e0172786.
    PubMed     Text format     Abstract available


  22. MARTINEZ-MARIN D, Jarvis C, Nelius T, de Riese W, et al
    PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.
    PLoS One. 2017;12:e0174968.
    PubMed     Text format     Abstract available


  23. ONUKWUGHA E, Kwok Y, Ciezki JP, Yong C, et al
    Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone.
    PLoS One. 2017;12:e0175956.
    PubMed     Text format     Abstract available


  24. AL AAMERI RFH, Sheth S, Alanisi EMA, Borse V, et al
    Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol.
    PLoS One. 2017;12:e0177198.
    PubMed     Text format     Abstract available


  25. OKEYO-OWUOR T, Benesh E, Bibbey S, Reid M, et al
    Exposure to maternal obesogenic diet worsens some but not all pre-cancer phenotypes in a murine genetic model of prostate cancer.
    PLoS One. 2017;12:e0175764.
    PubMed     Text format     Abstract available


  26. SCHUBERT C, Waletzko O, Weiss C, Voelzke D, et al
    Intercenter validation of a knowledge based model for automated planning of volumetric modulated arc therapy for prostate cancer. The experience of the German RapidPlan Consortium.
    PLoS One. 2017;12:e0178034.
    PubMed     Text format     Abstract available


  27. TENNILL TA, Gross ME, Frieboes HB
    Automated analysis of co-localized protein expression in histologic sections of prostate cancer.
    PLoS One. 2017;12:e0178362.
    PubMed     Text format     Abstract available


  28. DELOBEL JB, Gnep K, Ospina JD, Beckendorf V, et al
    Nomogram to predict rectal toxicity following prostate cancer radiotherapy.
    PLoS One. 2017;12:e0179845.
    PubMed     Text format     Abstract available


  29. RIVERA M, Ramos Y, Rodriguez-Valentin M, Lopez-Acevedo S, et al
    Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells.
    PLoS One. 2017;12:e0179587.
    PubMed     Text format     Abstract available


  30. ZEDAN AH, Blavnsfeldt SG, Hansen TF, Nielsen BS, et al
    Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations.
    PLoS One. 2017;12:e0179113.
    PubMed     Text format     Abstract available


  31. PASHAEI E, Pashaei E, Ahmady M, Ozen M, et al
    Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
    PLoS One. 2017;12:e0179543.
    PubMed     Text format     Abstract available


  32. ROY A, Ramalinga M, Kim OJ, Chijioke J, et al
    Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition.
    PLoS One. 2017;12:e0180344.
    PubMed     Text format     Abstract available


  33. POLANEC SH, Andrzejewski P, Baltzer PAT, Helbich TH, et al
    Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer.
    PLoS One. 2017;12:e0180790.
    PubMed     Text format     Abstract available


    January 2016
  34. PENG Z, Andersson K, Lindholm J, Dethlefsen O, et al
    Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material.
    PLoS One. 2016;11:e0145545.
    PubMed     Text format     Abstract available


  35. MOSCONI P, Colombo C, Satolli R, Carzaniga S, et al
    Involving a Citizens' Jury in Decisions on Individual Screening for Prostate Cancer.
    PLoS One. 2016;11:e0143176.
    PubMed     Text format     Abstract available


  36. NOVESKI P, Madjunkova S, Sukarova Stefanovska E, Matevska Geshkovska N, et al
    Loss of Y Chromosome in Peripheral Blood of Colorectal and Prostate Cancer Patients.
    PLoS One. 2016;11:e0146264.
    PubMed     Text format     Abstract available


  37. SHEN YH, Yang F, Wang H, Cai ZJ, et al
    Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice.
    PLoS One. 2016;11:e0147173.
    PubMed     Text format     Abstract available


  38. CIRCU ML, Dykes SS, Carroll J, Kelly K, et al
    A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion.
    PLoS One. 2016;11:e0146931.
    PubMed     Text format     Abstract available


  39. BASU A, Cajigas-Du Ross CK, Rios-Colon L, Mediavilla-Varela M, et al
    LEDGF/p75 Overexpression Attenuates Oxidative Stress-Induced Necrosis and Upregulates the Oxidoreductase ERP57/PDIA3/GRP58 in Prostate Cancer.
    PLoS One. 2016;11:e0146549.
    PubMed     Text format     Abstract available


  40. CHO Y, Chang JS, Rha KH, Hong SJ, et al
    Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?
    PLoS One. 2016;11:e0147191.
    PubMed     Text format     Abstract available


  41. LEE YI, Lee HM, Jo JK, Lee S, et al
    Association between Seminal Vesicle Invasion and Prostate Cancer Detection Location after Transrectal Systemic Biopsy among Men Who Underwent Radical Prostatectomy.
    PLoS One. 2016;11:e0148690.
    PubMed     Text format     Abstract available


  42. SCHLICK B, Massoner P, Lueking A, Charoentong P, et al
    Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.
    PLoS One. 2016;11:e0147739.
    PubMed     Text format     Abstract available


  43. DUSCHARLA D, Bhumireddy SR, Lakshetti S, Pospisil H, et al
    Prostate Cancer Associated Lipid Signatures in Serum Studied by ESI-Tandem Mass Spectrometryas Potential New Biomarkers.
    PLoS One. 2016;11:e0150253.
    PubMed     Text format     Abstract available


  44. SJOBLOM L, Saramaki O, Annala M, Leinonen K, et al
    Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
    PLoS One. 2016;11:e0150241.
    PubMed     Text format     Abstract available


  45. ALJAMEELI A, Thakkar A, Thomas S, Lakshmikanthan V, et al
    Calcitonin Receptor-Zonula Occludens-1 Interaction Is Critical for Calcitonin-Stimulated Prostate Cancer Metastasis.
    PLoS One. 2016;11:e0150090.
    PubMed     Text format     Abstract available


  46. HECKMAN MG, Robinson JL, Tzou KS, Parker AS, et al
    An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer.
    PLoS One. 2016;11:e0151785.
    PubMed     Text format     Abstract available


  47. FAJARDO AM, MacKenzie DA, Olguin SL, Scariano JK, et al
    Antioxidants Abrogate Alpha-Tocopherylquinone-Mediated Down-Regulation of the Androgen Receptor in Androgen-Responsive Prostate Cancer Cells.
    PLoS One. 2016;11:e0151525.
    PubMed     Text format     Abstract available


  48. KIM SH, Park WS, Kim SH, Park B, et al
    Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy.
    PLoS One. 2016;11:e0151646.
    PubMed     Text format     Abstract available


  49. CREMERS N, Neeb A, Uhle T, Dimmler A, et al
    CD24 Is Not Required for Tumor Initiation and Growth in Murine Breast and Prostate Cancer Models.
    PLoS One. 2016;11:e0151468.
    PubMed     Text format     Abstract available


  50. CIRCU ML, Dykes SS, Carroll J, Kelly K, et al
    Correction: A Novel High Content Imaging-Based Screen Identifies the Anti-Helminthic Niclosamide as an Inhibitor of Lysosome Anterograde Trafficking and Prostate Cancer Cell Invasion.
    PLoS One. 2016;11:e0151718.
    PubMed     Text format     Abstract available


  51. SUPARJI NS, Chan G, Sapili H, Arshad NM, et al
    Geranylated 4-Phenylcoumarins Exhibit Anticancer Effects against Human Prostate Cancer Cells through Caspase-Independent Mechanism.
    PLoS One. 2016;11:e0151472.
    PubMed     Text format     Abstract available


  52. LIANG M, Adisetiyo H, Li X, Liu R, et al
    Correction: Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model.
    PLoS One. 2016;11:e0152243.
    PubMed     Text format     Abstract available


  53. KIM DK, Koo KC, Abdel Raheem A, Kim KH, et al
    Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
    PLoS One. 2016;11:e0152391.
    PubMed     Text format     Abstract available


  54. SUNG SY, Chang JL, Chen KC, Yeh SD, et al
    Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth.
    PLoS One. 2016;11:e0153350.
    PubMed     Text format     Abstract available


  55. SALKELD G, Cunich M, Dowie J, Howard K, et al
    The Role of Personalised Choice in Decision Support: A Randomized Controlled Trial of an Online Decision Aid for Prostate Cancer Screening.
    PLoS One. 2016;11:e0152999.
    PubMed     Text format     Abstract available


  56. TOREN P, Kim S, Johnson F, Zoubeidi A, et al
    Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.
    PLoS One. 2016;11:e0152861.
    PubMed     Text format     Abstract available


  57. BRUREAU L, Moningo D, Emeville E, Ferdinand S, et al
    Polymorphisms of Estrogen Metabolism-Related Genes and Prostate Cancer Risk in Two Populations of African Ancestry.
    PLoS One. 2016;11:e0153609.
    PubMed     Text format     Abstract available


  58. ADELOYE D, David RA, Aderemi AV, Iseolorunkanmi A, et al
    An Estimate of the Incidence of Prostate Cancer in Africa: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0153496.
    PubMed     Text format     Abstract available


  59. RAHAL AK, Badgett RG, Hoffman RM
    Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review.
    PLoS One. 2016;11:e0153417.
    PubMed     Text format     Abstract available



  60. Correction: Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
    PLoS One. 2016;11:e0153732.
    PubMed     Text format     Abstract available


  61. TESSEM MB, Bertilsson H, Angelsen A, Bathen TF, et al
    A Balanced Tissue Composition Reveals New Metabolic and Gene Expression Markers in Prostate Cancer.
    PLoS One. 2016;11:e0153727.
    PubMed     Text format     Abstract available


  62. VEITONMAKI T, Murtola TJ, Talala K, Taari K, et al
    Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial.
    PLoS One. 2016;11:e0153413.
    PubMed     Text format     Abstract available


  63. PICKLES K, Carter SM, Rychetnik L, McCaffery K, et al
    General Practitioners' Experiences of, and Responses to, Uncertainty in Prostate Cancer Screening: Insights from a Qualitative Study.
    PLoS One. 2016;11:e0153299.
    PubMed     Text format     Abstract available


  64. KUBOTA Y, Kawamura H, Sakai M, Tsumuraya R, et al
    Changes in Rectal Dose Due to Alterations in Beam Angles for Setup Uncertainty and Range Uncertainty in Carbon-Ion Radiotherapy for Prostate Cancer.
    PLoS One. 2016;11:e0153894.
    PubMed     Text format     Abstract available


  65. TANG L, Li X, Wang B, Luo G, et al
    Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0153981.
    PubMed     Text format     Abstract available


  66. MOTAMEDINIA P, Scott AN, Bate KL, Sadeghi N, et al
    Urine Exosomes for Non-Invasive Assessment of Gene Expression and Mutations of Prostate Cancer.
    PLoS One. 2016;11:e0154507.
    PubMed     Text format     Abstract available


  67. YU T, Zhang Q, Zheng T, Shi H, et al
    The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures.
    PLoS One. 2016;11:e0154499.
    PubMed     Text format     Abstract available


  68. KIM JK, Kim HS, Park J, Jeong CW, et al
    Perioperative Blood Transfusion as a Significant Predictor of Biochemical Recurrence and Survival after Radical Prostatectomy in Patients with Prostate Cancer.
    PLoS One. 2016;11:e0154918.
    PubMed     Text format     Abstract available


  69. KHARMATE G, Hosseini-Beheshti E, Caradec J, Chin MY, et al
    Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes.
    PLoS One. 2016;11:e0154967.
    PubMed     Text format     Abstract available


  70. ALINEZHAD S, Vaananen RM, Mattsson J, Li Y, et al
    Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.
    PLoS One. 2016;11:e0155901.
    PubMed     Text format     Abstract available


  71. EL MAASSARANI M, Barbarin A, Fromont G, Kaissi O, et al
    Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant ErbB380kDa in Prostate Cancer Progression.
    PLoS One. 2016;11:e0155950.
    PubMed     Text format     Abstract available


  72. COSMA G, Acampora G, Brown D, Rees RC, et al
    Prediction of Pathological Stage in Patients with Prostate Cancer: A Neuro-Fuzzy Model.
    PLoS One. 2016;11:e0155856.
    PubMed     Text format     Abstract available


  73. BOTREL TE, Clark O, Lima Pompeo AC, Horta Bretas FF, et al
    Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0157660.
    PubMed     Text format     Abstract available


  74. BRYZGUNOVA OE, Zaripov MM, Skvortsova TE, Lekchnov EA, et al
    Comparative Study of Extracellular Vesicles from the Urine of Healthy Individuals and Prostate Cancer Patients.
    PLoS One. 2016;11:e0157566.
    PubMed     Text format     Abstract available


  75. KAYE DR, Pinto PA, Cecchi F, Reilly J, et al
    Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.
    PLoS One. 2016;11:e0157130.
    PubMed     Text format     Abstract available


  76. KHARMATE G, Hosseini-Beheshti E, Caradec J, Chin MY, et al
    Correction: Epidermal Growth Factor Receptor in Prostate Cancer Derived Exosomes.
    PLoS One. 2016;11:e0157392.
    PubMed     Text format     Abstract available


  77. LIN CY, Pakpour AH, Burri A, Montazeri A, et al
    Rasch Analysis of the Premature Ejaculation Diagnostic Tool (PEDT) and the International Index of Erectile Function (IIEF) in an Iranian Sample of Prostate Cancer Patients.
    PLoS One. 2016;11:e0157460.
    PubMed     Text format     Abstract available


  78. HO R, Siddiqui MM, George AK, Frye T, et al
    Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy.
    PLoS One. 2016;11:e0157313.
    PubMed     Text format     Abstract available


  79. ALINEZHAD S, Vaananen RM, Mattsson J, Li Y, et al
    Correction: Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.
    PLoS One. 2016;11:e0158255.
    PubMed     Text format     Abstract available


  80. EDMONDSON R, Adcock AF, Yang L
    Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins.
    PLoS One. 2016;11:e0158116.
    PubMed     Text format     Abstract available


  81. KANG YJ, Abalajon MJ, Jang WS, Kwon JK, et al
    Association of Anterior and Lateral Extraprostatic Extensions with Base-Positive Resection Margins in Prostate Cancer.
    PLoS One. 2016;11:e0158922.
    PubMed     Text format     Abstract available


  82. CAO J, Zhu X, Zhao X, Li XF, et al
    Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0158770.
    PubMed     Text format     Abstract available


  83. GOGOI P, Sepehri S, Zhou Y, Gorin MA, et al
    Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples.
    PLoS One. 2016;11:e0147400.
    PubMed     Text format     Abstract available


  84. KORSTEN H, Ziel-van der Made AC, van Weerden WM, van der Kwast T, et al
    Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice.
    PLoS One. 2016;11:e0147500.
    PubMed     Text format     Abstract available


  85. FARAJ SF, Bezerra SM, Yousefi K, Fedor H, et al
    Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy.
    PLoS One. 2016;11:e0146189.
    PubMed     Text format     Abstract available


  86. IPPOLITO JE, Brandenburg MW, Ge X, Crowley JR, et al
    Extracellular pH Modulates Neuroendocrine Prostate Cancer Cell Metabolism and Susceptibility to the Mitochondrial Inhibitor Niclosamide.
    PLoS One. 2016;11:e0159675.
    PubMed     Text format     Abstract available


  87. CONTEDUCA V, Crabb SJ, Jones RJ, Caffo O, et al
    Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.
    PLoS One. 2016;11:e0158952.
    PubMed     Text format     Abstract available


  88. LAWRENCE EM, Warren AY, Priest AN, Barrett T, et al
    Evaluating Prostate Cancer Using Fractional Tissue Composition of Radical Prostatectomy Specimens and Pre-Operative Diffusional Kurtosis Magnetic Resonance Imaging.
    PLoS One. 2016;11:e0159652.
    PubMed     Text format     Abstract available



  89. Retraction: Association of Polymorphism rs198977 in Human Kallikrein-2 Gene (KLK2) with Susceptibility of Prostate Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0160298.
    PubMed     Text format    


  90. ROETHKE MC, Kuru TH, Mueller-Wolf MB, Agterhuis E, et al
    Evaluation of an Automated Analysis Tool for Prostate Cancer Prediction Using Multiparametric Magnetic Resonance Imaging.
    PLoS One. 2016;11:e0159803.
    PubMed     Text format     Abstract available


  91. SEASHOLS-WILLIAMS SJ, Budd W, Clark GC, Wu Q, et al
    miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis.
    PLoS One. 2016;11:e0159601.
    PubMed     Text format     Abstract available


  92. PRETORIUS E, Africander DJ, Vlok M, Perkins MS, et al
    11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored.
    PLoS One. 2016;11:e0159867.
    PubMed     Text format     Abstract available


  93. QIN F, Song Y, Zhang Y, Facemire L, et al
    Role of CTCF in Regulating SLC45A3-ELK4 Chimeric RNA.
    PLoS One. 2016;11:e0150382.
    PubMed     Text format     Abstract available


  94. GRASSO C, Trevisan M, Fiano V, Tarallo V, et al
    Performance of Different Analytical Software Packages in Quantification of DNA Methylation by Pyrosequencing.
    PLoS One. 2016;11:e0150483.
    PubMed     Text format     Abstract available


  95. CAO H, Mu Y, Li X, Wang Y, et al
    A Systematic Review of Randomized Controlled Trials on Oral Chinese Herbal Medicine for Prostate Cancer.
    PLoS One. 2016;11:e0160253.
    PubMed     Text format     Abstract available


  96. THEIL G, Fischer K, Weber E, Medek R, et al
    The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.
    PLoS One. 2016;11:e0158354.
    PubMed     Text format     Abstract available


  97. PASQUIER D, Boutaud de la Combe-Chossiere L, Carlier D, Darloy F, et al
    Harmonization of the Volume of Interest Delineation among All Eleven Radiotherapy Centers in the North of France.
    PLoS One. 2016;11:e0150917.
    PubMed     Text format     Abstract available


  98. MEYER HE, Stoer NC, Samuelsen SO, Blomhoff R, et al
    Long Term Association between Serum 25-Hydroxyvitamin D and Mortality in a Cohort of 4379 Men.
    PLoS One. 2016;11:e0151441.
    PubMed     Text format     Abstract available


  99. YANG K, Wu WM, Chen YC, Lo SH, et al
    DeltaNp63alpha Transcriptionally Regulates the Expression of CTEN That Is Associated with Prostate Cell Adhesion.
    PLoS One. 2016;11:e0147542.
    PubMed     Text format     Abstract available


  100. REIGSTAD I, Smeland HY, Skogstrand T, Sortland K, et al
    Stromal Integrin alpha11beta1 Affects RM11 Prostate and 4T1 Breast Xenograft Tumors Differently.
    PLoS One. 2016;11:e0151663.
    PubMed     Text format     Abstract available


  101. GUO J, Wang M, Wang Z, Liu X, et al
    Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
    PLoS One. 2016;11:e0158667.
    PubMed     Text format     Abstract available


  102. TOTH R, Sperling D, Madabhushi A
    Quantifying Post- Laser Ablation Prostate Therapy Changes on MRI via a Domain-Specific Biomechanical Model: Preliminary Findings.
    PLoS One. 2016;11:e0150016.
    PubMed     Text format     Abstract available


  103. BOEGEMANN M, Schlack K, Fischer AK, Gerss J, et al
    Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.
    PLoS One. 2016;11:e0161959.
    PubMed     Text format     Abstract available


  104. TSOI TH, Chan CF, Chan WL, Chiu KF, et al
    Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
    PLoS One. 2016;11:e0162217.
    PubMed     Text format     Abstract available


  105. MORELL C, Bort A, Vara-Ciruelos D, Ramos-Torres A, et al
    Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells.
    PLoS One. 2016;11:e0162977.
    PubMed     Text format     Abstract available


  106. PENG F, Li H, Ning Z, Yang Z, et al
    CD147 and Prostate Cancer: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0163678.
    PubMed     Text format     Abstract available


  107. HAYANO T, Matsui H, Nakaoka H, Ohtake N, et al
    Germline Variants of Prostate Cancer in Japanese Families.
    PLoS One. 2016;11:e0164233.
    PubMed     Text format     Abstract available


  108. MILOSAVLJEVIC V, Haddad Y, Merlos Rodrigo MA, Moulick A, et al
    The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.
    PLoS One. 2016;11:e0163983.
    PubMed     Text format     Abstract available


  109. POLLACK CE, Ross ME, Armstrong K, Branas CC, et al
    Using a Mystery-Caller Approach to Examine Access to Prostate Cancer Care in Philadelphia.
    PLoS One. 2016;11:e0164411.
    PubMed     Text format     Abstract available


  110. HAMMARSTEN P, Dahl Scherdin T, Hagglof C, Andersson P, et al
    High Caveolin-1 Expression in Tumor Stroma Is Associated with a Favourable Outcome in Prostate Cancer Patients Managed by Watchful Waiting.
    PLoS One. 2016;11:e0164016.
    PubMed     Text format     Abstract available


  111. BURTON LJ, Rivera M, Hawsawi O, Zou J, et al
    Muscadine Grape Skin Extract Induces an Unfolded Protein Response-Mediated Autophagy in Prostate Cancer Cells: A TMT-Based Quantitative Proteomic Analysis.
    PLoS One. 2016;11:e0164115.
    PubMed     Text format     Abstract available


  112. LUTJE S, Blex S, Gomez B, Schaarschmidt BM, et al
    Optimization of Acquisition time of 68Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer.
    PLoS One. 2016;11:e0164392.
    PubMed     Text format     Abstract available


  113. KARLSSON T, Lundholm M, Widmark A, Persson E, et al
    Tumor Cell-Derived Exosomes from the Prostate Cancer Cell Line TRAMP-C1 Impair Osteoclast Formation and Differentiation.
    PLoS One. 2016;11:e0166284.
    PubMed     Text format     Abstract available


  114. BELLOMO G, Marcocci F, Bianchini D, Mezzenga E, et al
    MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification.
    PLoS One. 2016;11:e0165730.
    PubMed     Text format     Abstract available


  115. LANDSHEER JA
    Interval of Uncertainty: An Alternative Approach for the Determination of Decision Thresholds, with an Illustrative Application for the Prediction of Prostate Cancer.
    PLoS One. 2016;11:e0166007.
    PubMed     Text format     Abstract available


  116. MAHMOUD AM, Al-Alem U, Dabbous F, Ali MM, et al
    Zinc Intake and Risk of Prostate Cancer: Case-Control Study and Meta-Analysis.
    PLoS One. 2016;11:e0165956.
    PubMed     Text format     Abstract available


  117. HEGER Z, Merlos Rodrigo MA, Michalek P, Polanska H, et al
    Sarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer.
    PLoS One. 2016;11:e0165830.
    PubMed     Text format     Abstract available


  118. ZHANG K, Shen Y, Zhang X, Ma L, et al
    Predicting Prostate Biopsy Outcomes: A Preliminary Investigation on Screening with Ultrahigh B-Value Diffusion-Weighted Imaging as an Innovative Diagnostic Biomarker.
    PLoS One. 2016;11:e0151176.
    PubMed     Text format     Abstract available


  119. EMINAGA O, Wei W, Hawley SJ, Auman H, et al
    MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study.
    PLoS One. 2016;11:e0165236.
    PubMed     Text format     Abstract available


  120. LEE J, Han JH, Jang A, Kim JW, et al
    DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells.
    PLoS One. 2016;11:e0166664.
    PubMed     Text format     Abstract available


  121. REIS ST, Viana NI, Leite KR, Diogenes E, et al
    Role of Genetic Polymorphisms in the Development and Prognosis of Sporadic and Familial Prostate Cancer.
    PLoS One. 2016;11:e0166380.
    PubMed     Text format     Abstract available


  122. SADEGHI M, Ranjbar B, Ganjalikhany MR, M Khan F, et al
    MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression.
    PLoS One. 2016;11:e0168760.
    PubMed     Text format     Abstract available


  123. MARANO F, Rinella L, Argenziano M, Cavalli R, et al
    Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves.
    PLoS One. 2016;11:e0168553.
    PubMed     Text format     Abstract available


  124. ORAL E, Simonsen N, Brennan C, Berken J, et al
    Unit Nonresponse in a Population-Based Study of Prostate Cancer.
    PLoS One. 2016;11:e0168364.
    PubMed     Text format     Abstract available


  125. BLACKLEDGE MD, Tunariu N, Orton MR, Padhani AR, et al
    Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease.
    PLoS One. 2016;11:e0153840.
    PubMed     Text format     Abstract available


  126. APRELIKOVA O, Tomlinson CC, Hoenerhoff M, Hixon JA, et al
    Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
    PLoS One. 2016;11:e0155262.
    PubMed     Text format     Abstract available


  127. MASOOMPOUR SM, Lankarani KB, Honarvar B, Tabatabaee SH, et al
    Changing Epidemiology of Common Cancers in Southern Iran, 2007-2010: A Cross Sectional Study.
    PLoS One. 2016;11:e0155669.
    PubMed     Text format     Abstract available


    January 2015
  128. KHALID T, Aggio R, White P, De Lacy Costello B, et al
    Urinary Volatile Organic Compounds for the Detection of Prostate Cancer.
    PLoS One. 2015;10:e0143283.
    PubMed     Text format     Abstract available


  129. HUANG H, Chen X, Li D, He Y, et al
    Combination of alpha-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells.
    PLoS One. 2015;10:e0144293.
    PubMed     Text format     Abstract available


  130. LIU C, Guan H, Wang Y, Chen M, et al
    miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer Cells.
    PLoS One. 2015;10:e0144073.
    PubMed     Text format     Abstract available


  131. BALVAN J, Gumulec J, Raudenska M, Krizova A, et al
    Oxidative Stress Resistance in Metastatic Prostate Cancer: Renewal by Self-Eating.
    PLoS One. 2015;10:e0145016.
    PubMed     Text format     Abstract available


  132. KOCARNIK JM, Park SL, Han J, Dumitrescu L, et al
    Pleiotropic and Sex-Specific Effects of Cancer GWAS SNPs on Melanoma Risk in the Population Architecture Using Genomics and Epidemiology (PAGE) Study.
    PLoS One. 2015;10:e0120491.
    PubMed     Text format     Abstract available


  133. LINN DE, Bronson RT, Li Z
    Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    PLoS One. 2015;10:e0120628.
    PubMed     Text format     Abstract available


  134. BELL EH, Kirste S, Fleming JL, Stegmaier P, et al
    A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapy.
    PLoS One. 2015;10:e0118745.
    PubMed     Text format     Abstract available


  135. MYERS JS, von Lersner AK, Robbins CJ, Sang QX, et al
    Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.
    PLoS One. 2015;10:e0145322.
    PubMed     Text format     Abstract available


  136. LU Y, Starkey N, Lei W, Li J, et al
    Inhibition of Hedgehog-Signaling Driven Genes in Prostate Cancer Cells by Sutherlandia frutescens Extract.
    PLoS One. 2015;10:e0145507.
    PubMed     Text format     Abstract available


  137. JONES AC, Antillon KS, Jenkins SM, Janos SN, et al
    Prostate field cancerization: deregulated expression of macrophage inhibitory cytokine 1 (MIC-1) and platelet derived growth factor A (PDGF-A) in tumor adjacent tissue.
    PLoS One. 2015;10:e0119314.
    PubMed     Text format     Abstract available


  138. REDANIEL MT, Martin RM, Ridd MJ, Wade J, et al
    Diagnostic intervals and its association with breast, prostate, lung and colorectal cancer survival in England: historical cohort study using the clinical practice research datalink.
    PLoS One. 2015;10:e0126608.
    PubMed     Text format     Abstract available


  139. ASSI J, Srivastava G, Matta A, MacMillan C, et al
    Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.
    PLoS One. 2015;10:e0107586.
    PubMed     Text format     Abstract available


  140. SAFFARINI CM, McDonnell-Clark EV, Amin A, Huse SM, et al
    Developmental exposure to estrogen alters differentiation and epigenetic programming in a human fetal prostate xenograft model.
    PLoS One. 2015;10:e0122290.
    PubMed     Text format     Abstract available


  141. KANG M, Jeong CW, Ku JH, Kwak C, et al
    Hypertriglyceridemia is a potential preoperative predictor for biochemical recurrence after radical prostatectomy.
    PLoS One. 2015;10:e0122438.
    PubMed     Text format     Abstract available


  142. KANAOKA R, Kushiyama A, Seno Y, Nakatsu Y, et al
    Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines.
    PLoS One. 2015;10:e0127467.
    PubMed     Text format     Abstract available


  143. MORAIS-SANTOS M, Nunes AE, Oliveira AG, Moura-Cordeiro JD, et al
    Changes in Estrogen Receptor ERbeta (ESR2) Expression without Changes in the Estradiol Levels in the Prostate of Aging Rats.
    PLoS One. 2015;10:e0131901.
    PubMed     Text format     Abstract available


  144. HIRATA Y, Morino K, Akakura K, Higano CS, et al
    Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy.
    PLoS One. 2015;10:e0130372.
    PubMed     Text format     Abstract available


  145. BICKER A, Brahmer AM, Meller S, Kristiansen G, et al
    The Distinct Gene Regulatory Network of Myoglobin in Prostate and Breast Cancer.
    PLoS One. 2015;10:e0142662.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: